StudyLancet review: cannabinoids in chronic non-cancer pain — updated evidence synthesisRegulatoryGermany: BfArM publishes updated guidance on medicinal cannabis prescribingStudyNEJM: CBD adjunctive therapy in treatment-resistant epilepsy — long-term follow-upRegulatoryTGA Australia releases revised Special Access Scheme statisticsBusinessTilray and Aphria file expanded EU-GMP medical cannabis distribution agreementsRegulatoryUK MHRA consults on unlicensed cannabis-based medicinal products frameworkStudyJAMA: cannabinoids in chemotherapy-induced nausea — systematic review updateBusinessCanopy Growth restructures European operations amid German market expansionRegulatorySwissmedic authorises additional medicinal cannabis product classificationsStudyIACM publishes 2026 international consensus on cannabinoid dosing in palliative careStudyLancet review: cannabinoids in chronic non-cancer pain — updated evidence synthesisRegulatoryGermany: BfArM publishes updated guidance on medicinal cannabis prescribingStudyNEJM: CBD adjunctive therapy in treatment-resistant epilepsy — long-term follow-upRegulatoryTGA Australia releases revised Special Access Scheme statisticsBusinessTilray and Aphria file expanded EU-GMP medical cannabis distribution agreementsRegulatoryUK MHRA consults on unlicensed cannabis-based medicinal products frameworkStudyJAMA: cannabinoids in chemotherapy-induced nausea — systematic review updateBusinessCanopy Growth restructures European operations amid German market expansionRegulatorySwissmedic authorises additional medicinal cannabis product classificationsStudyIACM publishes 2026 international consensus on cannabinoid dosing in palliative care
News & Research

Scientific updates, journal club and international perspective.

Scientific updateMarch 2026

CB2 receptor signalling in chronic inflammatory pain: what the latest reviews tell us.

A concise summary written for practising professionals — with links to the primary sources and a clinical takeaway.

Read →
Journal clubFebruary 2026

Systematic review: cannabinoids in chemotherapy-induced nausea, an updated appraisal.

A concise summary written for practising professionals — with links to the primary sources and a clinical takeaway.

Read →
RegulatoryFebruary 2026

Germany six months on: early clinical observations following legal reform.

A concise summary written for practising professionals — with links to the primary sources and a clinical takeaway.

Read →
Clinical reviewJanuary 2026

CBD in refractory epilepsy: consolidating the evidence beyond Dravet and LGS.

A concise summary written for practising professionals — with links to the primary sources and a clinical takeaway.

Read →
Conference reportDecember 2025

IACM 2025: highlights from the international cannabinoid research meeting.

A concise summary written for practising professionals — with links to the primary sources and a clinical takeaway.

Read →
Expert opinionNovember 2025

Responsible prescribing frameworks: lessons from three jurisdictions.

A concise summary written for practising professionals — with links to the primary sources and a clinical takeaway.

Read →